Search Results - "Neill, Jo C"
-
1
A systematic review and meta-analysis of cognitive remediation in early schizophrenia
Published in Schizophrenia research (01-10-2015)“…Abstract Neurocognitive impairment predicts disability in schizophrenia, making intervention theoretically attractive as a means to minimise chronic…”
Get full text
Journal Article -
2
Nicotinic α7 and α4β2 agonists enhance the formation and retrieval of recognition memory: Potential mechanisms for cognitive performance enhancement in neurological and psychiatric disorders
Published in Behavioural brain research (01-04-2016)“…•Object recognition memory decays to 0 after a 6h ITI in female hL rats.•Activation of nicotinic α7 and α4b2 receptors restores this memory.•Donepezil restores…”
Get full text
Journal Article -
3
Activation of α7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: Implications for therapy of cognitive dysfunction in schizophrenia
Published in European neuropsychopharmacology (01-04-2011)“…Abstract Rationale Nicotinic α7 acetylcholine receptors (nAChRs) have been highlighted as a target for cognitive enhancement in schizophrenia. Aim To…”
Get full text
Journal Article -
4
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Published in Journal of Psychopharmacology (01-03-2022)“…Background: Despite an increasing body of research highlighting their efficacy to treat a broad range of medical conditions, psychedelic drugs remain a…”
Get full text
Book Review Journal Article -
5
Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats
Published in Behavioural brain research (11-02-2010)“…Cognitive deficits are a major clinical unmet need in schizophrenia. The psychotomimetic drug phencyclidine (PCP) is widely applied in rodents to mimic…”
Get full text
Journal Article -
6
Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat
Published in Behavioural brain research (25-12-2010)“…Asenapine is a new pharmacological agent for the acute treatment of schizophrenia and bipolar disorder. It has relatively higher affinity for serotonergic and…”
Get full text
Journal Article -
7
D1 receptor activation improves vigilance in rats as measured by the 5-choice continuous performance test
Published in Psychopharmacologia (01-03-2012)“…Rationale Impaired attention/vigilance is putatively core to schizophrenia. The dopaminergic D 1 receptor system has been reported as one of the most promising…”
Get full text
Journal Article -
8
Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology
Published in European neuropsychopharmacology (01-01-2016)“…Abstract Negative symptoms and cognitive impairment associated with schizophrenia are strongly associated with poor functional outcome and reduced quality of…”
Get full text
Journal Article -
9
Luvadaxistat: A Novel Potent and Selective d-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia
Published in Neurochemical research (01-10-2023)“…N-methyl- d -aspartate (NMDA) receptor hypofunctionality is a well-studied hypothesis for schizophrenia pathophysiology, and daily dosing of the NMDA receptor…”
Get full text
Journal Article -
10
-
11
Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism
Published in Psychopharmacologia (01-04-2011)“…Rationale Cognitive deficits are common in schizophrenia. Asenapine is an atypical antipsychotic approved by the US Food and Drug Administration in adults for…”
Get full text
Journal Article -
12
Extrasynaptic GABAA receptor activation reverses recognition memory deficits in an animal model of schizophrenia
Published in Psychopharmacologia (01-03-2011)“…Rationale Schizophrenia is a complex psychiatric disorder comprised of three main classes of symptoms: positive, negative and cognitive symptoms. Currently, no…”
Get full text
Journal Article -
13
Nicotinic alpha 7 and alpha 4 beta 2 agonists enhance the formation and retrieval of recognition memory: Potential mechanisms for cognitive performance enhancement in neurological and psychiatric disorders
Published in Behavioural brain research (01-04-2016)“…Cholinergic dysfunction has been shown to be central to the pathophysiology of Alzheimer's disease and has also been postulated to contribute to cognitive…”
Get full text
Journal Article -
14
Rats tested after a washout period from sub-chronic PCP administration exhibited impaired performance in the 5-Choice Continuous Performance Test (5C-CPT) when the attentional load was increased
Published in Neuropharmacology (01-03-2012)“…It is well documented that schizophrenia patients exhibit dysfunction in various cognitive domains, including attention/vigilance, as demonstrated by impaired…”
Get full text
Journal Article -
15
PNU-120596, a positive allosteric modulator of alpha 7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats
Published in Journal of psychopharmacology (Oxford) (01-09-2012)“…The alpha 7 nicotinic acetylcholine receptors (nAChRs) have been highlighted as a target for cognitive enhancement in schizophrenia. Adult female hooded Lister…”
Get full text
Journal Article -
16
PNU-120596, a positive allosteric modulator of α7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats
Published in Journal of psychopharmacology (Oxford) (01-09-2012)“…The α7 nicotinic acetylcholine receptors (nAChRs) have been highlighted as a target for cognitive enhancement in schizophrenia. Adult female hooded Lister rats…”
Get full text
Journal Article -
17
The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania
Published in Expert opinion on drug discovery (01-01-2013)“…Asenapine is a novel antipsychotic drug approved for the treatment of acute schizophrenia, manic, or mixed episodes associated with bipolar I disorder, as a…”
Get more information
Journal Article -
18
Activation of alpha 7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: Implications for therapy of cognitive dysfunction in schizophrenia
Published in European neuropsychopharmacology (01-04-2011)“…Nicotinic alpha 7 acetylcholine receptors (nAChRs) have been highlighted as a target for cognitive enhancement in schizophrenia. Aim: To investigate whether…”
Get full text
Journal Article -
19
Impaired limbic cortico-striatal structure and sustained visual attention in a rodent model of schizophrenia
Published in The international journal of neuropsychopharmacology (01-01-2015)“…N-methyl-d-aspartate receptor (NMDAR) dysfunction is thought to contribute to the pathophysiology of schizophrenia. Accordingly, NMDAR antagonists such as…”
Get full text
Journal Article -
20
First episode psychosis patients show impaired cognitive function – a study of a South Asian population in the UK
Published in Journal of psychopharmacology (Oxford) (01-04-2013)“…Background: Cognitive deficits are a core symptom of schizophrenia, severely debilitating and untreated by current medication. However, to date there is…”
Get full text
Journal Article